FDA reg review targets three-quarters of rules for deletion or modification.
This article was originally published in The Gray Sheet
Executive Summary
FDA REG REVIEW TARGETS THREE-QUARTERS OF AGENCY RULES for deletion or "reinvention," FDA Office of External Affairs Deputy Commissioner Sharon Smith Holston said June 21 at the National Association of Pharmaceutical Manufacturers mid-year meeting in Washington, D.C. Over the past year, FDA has conducted a line-by-line review of its regulations and found that over 1,300 pages could be deleted or modified. The review excluded rules concerning product approvals and classifications.